 [1m([0morchestrator-gastrointestinal ulcer hospitalization-TIGECYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes TIGECYCLINE increase or decrease the risk[0m
[34mof gastrointestinal ulcer hospitalization?[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-TIGECYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-TIGECYCLINE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-TIGECYCLINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does TIGECYCLINE increase or decrease the risk of gastrointestinal ulcer hospitalization?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-TIGECYCLINE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes TIGECYCLINE increase or decrease the risk[0m
[32mof gastrointestinal ulcer hospitalization?[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-TIGECYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-TIGECYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-TIGECYCLINE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes TIGECYCLINE increase or decrease the risk of gastrointestinal ulcer hospitalization?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does TIGECYCLINE increase or decrease the risk of gastrointestinal ulcer hospitalization?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"tigecycline"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: TIGECYCLINE: clinical_studies_table: [0m[1;31m<[0m[1;31mtable[0m[31m [0m[31mID[0m[31m=[0m[31m"t11"[0m[31m [0m[31mwidth[0m[31m=[0m[31m"100[0m[31m%"[0m[31m><caption [0m[31mID[0m[31m=[0m[31m"G27e24559[0m[31m-6ed6-49f7-a922-9571f94945ca"[0m[31m>Table [0m[1;31m10[0m[31m. Post-hoc Analysis of Clinical Cure Rates in Patients with [0m
[31mCommunity-Acquired Bacterial Pneumonia Based on Risk of Mortality<sup>a<[0m[31m/[0m[31msup[0m[31m><[0m[31m/[0m[31mcaption[0m[31m><colgroup><col [0m[31malign[0m[31m=[0m[31m"left"[0m[31m [0m[31mwidth[0m[31m=[0m[31m"25[0m[31m%"[0m[31m/[0m[31m><col [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mwidth[0m[31m=[0m[31m"25[0m[31m%"[0m[31m/[0m[31m><col [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mwidth[0m[31m=[0m[31m"25[0m[31m%"[0m[31m/[0m[31m><col [0m
[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mwidth[0m[31m=[0m[31m"25[0m[31m%"[0m[31m/[0m[31m><[0m[31m/[0m[31mcolgroup[0m[31m><thead><tr><th/><th>Tigecycline for injection<[0m[31m/[0m[31mth[0m[31m><th>Levofloxacin<[0m[31m/[0m[31mth[0m[31m><th/><[0m[31m/[0m[31mtr[0m[31m><tr><th/><th>n/N [0m[1;31m([0m[31m%[0m[1;31m)[0m[31m <[0m[31m/[0m[31mth[0m[31m><th>n/N [0m[1;31m([0m[31m%[0m[1;31m)[0m[31m <[0m[31m/[0m[31mth[0m[31m><th>[0m[1;31m95[0m[31m% [0m
[31mCI<sup>b<[0m[31m/[0m[31msup[0m[31m><[0m[31m/[0m[31mth[0m[31m><[0m[31m/[0m[31mtr[0m[31m><[0m[31m/[0m[31mthead[0m[31m><tfoot><tr><td [0m[31mcolspan[0m[31m=[0m[31m"4"[0m[31m><sup>a<[0m[31m/[0m[31msup[0m[31m TIGECYCLINE: clinical_studies_table: > Patients at higher risk of death include patients with any one of the following: [0m
[31m&#x2265;[0m[1;31m50[0m[31m year of age; PSI score &#x2265;[0m[1;31m3[0m[31m; or bacteremia due to <content [0m[31mstyleCode[0m[31m=[0m[31m"italics"[0m[31m>Streptococcus pneumoniae<[0m[31m/[0m[31mcontent[0m[31m><paragraph><sup>b<[0m[31m/[0m[31msup[0m[31m> [0m[1;31m95[0m[31m% confidence interval for the treatment [0m
[31mdifference<[0m[31m/[0m[31mparagraph[0m[31m><paragraph><sup>c<[0m[31m/[0m[31msup[0m[31m> After at least [0m[1;31m3[0m[31m days of intravenous therapy, a switch to oral levofloxacin [0m[1;31m([0m[1;31m500[0m[31m mg daily[0m[1;31m)[0m[31m was permitted for both treatment arms in Study [0m[1;31m1[0m[31m. TIGECYCLINE: [0m
[31mclinical_studies_table: paragraph><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><[0m[31m/[0m[31mtfoot[0m[31m><tbody><tr><td>Study [0m[1;31m1[0m[31m<sup>c<[0m[31m/[0m[31msup[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> CE <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Higher risk [0m
[31m<[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Yes <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m93[0m[31m/[0m[1;31m103[0m[31m [0m[1;31m([0m[1;31m90.3[0m[1;31m)[0m[31m [0m
[31m<[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m84[0m[31m/[0m[1;31m102[0m[31m [0m[1;31m([0m[1;31m82[0m[31m. TIGECYCLINE: clinical_studies_table: [0m[1;31m4[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m([0m[1;31m-2.3[0m[31m, [0m[1;31m18.2[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> No <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m32[0m[31m/[0m[1;31m35[0m[31m [0m[1;31m([0m[1;31m91.4[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m52[0m[31m/[0m[1;31m54[0m[31m [0m[1;31m([0m[1;31m96.3[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m([0m[1;31m-20.8[0m[31m, [0m[1;31m7[0m[31m. TIGECYCLINE: clinical_studies_table: [0m[1;31m1[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> c-mITT [0m
[31m<[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Higher risk <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> [0m
[31m<[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Yes <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m111[0m[31m/[0m[1;31m142[0m[31m [0m[1;31m([0m[1;31m78.2[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m100[0m[31m/[0m[1;31m134[0m[31m [0m[1;31m([0m[1;31m74.6[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m([0m[1;31m-6.9[0m[31m, [0m[1;31m14[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> No <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m38[0m[31m/[0m[1;31m49[0m[31m [0m[1;31m([0m[1;31m77[0m[31m. TIGECYCLINE: clinical_studies_table: [0m[1;31m6[0m[1;31m)[0m[31m [0m
[31m<[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m58[0m[31m/[0m[1;31m69[0m[31m [0m[1;31m([0m[1;31m84.1[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m([0m[1;31m-22.8[0m[31m, [0m[1;31m8[0m[31m. TIGECYCLINE: clinical_studies_table: [0m[1;31m7[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td>Study [0m[1;31m2[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> CE <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Higher risk <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Yes <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m95[0m[31m/[0m[1;31m107[0m[31m [0m[1;31m([0m[1;31m88[0m[31m. TIGECYCLINE: clinical_studies_table: [0m[1;31m8[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m68[0m[31m/[0m[1;31m85[0m[31m [0m[1;31m([0m[1;31m80[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m
[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m([0m[1;31m-2.2[0m[31m, [0m[1;31m20.3[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> No <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m33[0m[31m/[0m[1;31m37[0m[31m [0m[1;31m([0m[1;31m89.2[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m48[0m[31m/[0m[1;31m51[0m[31m [0m[1;31m([0m[1;31m94.1[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m([0m[1;31m-21.1[0m[31m, [0m[1;31m8[0m[31m. TIGECYCLINE: clinical_studies_table: [0m[1;31m6[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> c-mITT <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Higher risk <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Yes [0m
[31m<[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m112[0m[31m/[0m[1;31m134[0m[31m [0m[1;31m([0m[1;31m83.6[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m93[0m[31m/[0m[1;31m120[0m[31m [0m[1;31m([0m[1;31m77.5[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m([0m[1;31m-4.2[0m[31m, [0m[1;31m16.4[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> No <[0m[31m/[0m[31mtd[0m[31m><td [0m
[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m58[0m[31m/[0m[1;31m69[0m[31m [0m[1;31m([0m[1;31m84[0m[31m. TIGECYCLINE: clinical_studies_table: [0m[1;31m1[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m70[0m[31m/[0m[1;31m80[0m[31m [0m[1;31m([0m[1;31m87.5[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m([0m[1;31m-16.2[0m[31m, [0m[1;31m8[0m[31m. TIGECYCLINE: [0m
[31mclinical_studies_table: [0m[1;31m8[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><[0m[31m/[0m[31mtbody[0m[31m><[0m[31m/[0m[31mtable[0m[31m>         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: clinical_studies: [0m[1;31m3[0m[1;31m)[0m[31m Legionella pneumophila [0m[1;31m10[0m[31m/[0m[1;31m10[0m[31m [0m[1;31m([0m[1;31m100.0[0m[1;31m)[0m[31m [0m[1;31m6[0m[31m/[0m[1;31m6[0m[31m [0m[1;31m([0m[1;31m100.0[0m[1;31m)[0m[31m Streptococcus pneumoniae [0m[1;31m([0m[31mpenicillin-susceptible only[0m[1;31m)[0m[31m b [0m[1;31m44[0m[31m/[0m[1;31m46[0m[31m [0m[1;31m([0m[1;31m95.7[0m[1;31m)[0m[31m [0m[1;31m39[0m[31m/[0m[1;31m44[0m[31m [0m[1;31m([0m[1;31m88.6[0m[1;31m)[0m[31m To further evaluate the [0m
[31mtreatment effect of tigecycline, a post-hoc analysis was conducted in CABP patients with a higher risk of mortality, for whom the treatment effect of antibacterial drugs is supported by historical [0m
[31mevidence. The higher-risk group included CABP patients from the two studies with any of the following factors: Age â‰¥[0m[1;31m50[0m[31m years PSI score â‰¥[0m[1;31m3[0m[31m Streptococcus pneumoniae bacteremia The results of this [0m
[31manalysis are shown in Table [0m[1;31m10[0m[31m. Age â‰¥[0m[1;31m50[0m[31m was the most common risk factor in the higher-risk group. Table [0m[1;31m10[0m[31m. TIGECYCLINE: clinical_studies: Post-hoc Analysis of Clinical Cure Rates in Patients with [0m
[31mCommunity-Acquired Bacterial Pneumonia Based on Risk of Mortality a Tigecycline for injection Levofloxacin n/N [0m[1;31m([0m[31m%[0m[1;31m)[0m[31m n/N [0m[1;31m([0m[31m%[0m[1;31m)[0m[31m [0m[1;31m95[0m[31m% CI b a Patients at higher risk of death include patients with any one of [0m
[31mthe following: â‰¥[0m[1;31m50[0m[31m year of age; PSI score â‰¥[0m[1;31m3[0m[31m; or bacteremia due to Streptococcus pneumoniae b [0m[1;31m95[0m[31m% confidence interval for the treatment difference c After at least [0m[1;31m3[0m[31m days of intravenous therapy, a [0m
[31mswitch to oral levofloxacin [0m[1;31m([0m[1;31m500[0m[31m mg daily[0m[1;31m)[0m[31m was permitted for both treatment arms in Study [0m[1;31m1[0m[31m. Study [0m[1;31m1[0m[31m c CE Higher risk Yes [0m[1;31m93[0m[31m/[0m[1;31m103[0m[31m [0m[1;31m([0m[1;31m90.3[0m[1;31m)[0m[31m [0m[1;31m84[0m[31m/[0m[1;31m102[0m[31m [0m[1;31m([0m[1;31m82.4[0m[1;31m)[0m[31m [0m[1;31m([0m[1;31m-2.3[0m[31m, [0m[1;31m18.2[0m[1;31m)[0m[31m No [0m[1;31m32[0m[31m/[0m[1;31m35[0m[31m [0m[1;31m([0m[1;31m91.4[0m[1;31m)[0m[31m [0m[1;31m52[0m[31m/[0m[1;31m54[0m[31m [0m[1;31m([0m[1;31m96.3[0m[1;31m)[0m[31m [0m[1;31m([0m[1;31m-20.8[0m[31m, [0m
[1;31m7[0m[31m. TIGECYCLINE: clinical_studies: [0m[1;31m1[0m[1;31m)[0m[31m c-mITT Higher risk Yes [0m[1;31m111[0m[31m/[0m[1;31m142[0m[31m [0m[1;31m([0m[1;31m78.2[0m[1;31m)[0m[31m [0m[1;31m100[0m[31m/[0m[1;31m134[0m[31m [0m[1;31m([0m[1;31m74.6[0m[1;31m)[0m[31m [0m[1;31m([0m[1;31m-6.9[0m[31m, [0m[1;31m14[0m[1;31m)[0m[31m No [0m[1;31m38[0m[31m/[0m[1;31m49[0m[31m [0m[1;31m([0m[1;31m77.6[0m[1;31m)[0m[31m [0m[1;31m58[0m[31m/[0m[1;31m69[0m[31m [0m[1;31m([0m[1;31m84.1[0m[1;31m)[0m[31m [0m[1;31m([0m[1;31m-22.8[0m[31m, [0m[1;31m8.7[0m[1;31m)[0m[31m Study [0m[1;31m2[0m[31m CE Higher risk Yes [0m[1;31m95[0m[31m/[0m[1;31m107[0m[31m [0m[1;31m([0m[1;31m88.8[0m[1;31m)[0m[31m [0m[1;31m68[0m[31m/[0m[1;31m85[0m[31m [0m[1;31m([0m[1;31m80[0m[1;31m)[0m[31m [0m
[1;31m([0m[1;31m-2.2[0m[31m, [0m[1;31m20.3[0m[1;31m)[0m[31m No [0m[1;31m33[0m[31m/[0m[1;31m37[0m[31m [0m[1;31m([0m[1;31m89.2[0m[1;31m)[0m[31m [0m[1;31m48[0m[31m/[0m[1;31m51[0m[31m [0m[1;31m([0m[1;31m94.1[0m[1;31m)[0m[31m [0m[1;31m([0m[1;31m-21.1[0m[31m, [0m[1;31m8.6[0m[1;31m)[0m[31m c-mITT Higher risk Yes [0m[1;31m112[0m[31m/[0m[1;31m134[0m[31m [0m[1;31m([0m[1;31m83.6[0m[1;31m)[0m[31m [0m[1;31m93[0m[31m/[0m[1;31m120[0m[31m [0m[1;31m([0m[1;31m77.5[0m[1;31m)[0m[31m [0m[1;31m([0m[1;31m-4.2[0m[31m, [0m[1;31m16.4[0m[1;31m)[0m[31m No [0m[1;31m58[0m[31m/[0m[1;31m69[0m[31m [0m[1;31m([0m[1;31m84.1[0m[1;31m)[0m[31m [0m[1;31m70[0m[31m/[0m[1;31m80[0m[31m [0m[1;31m([0m[1;31m87.5[0m[1;31m)[0m[31m [0m[1;31m([0m[1;31m-16.2[0m[31m, [0m[1;31m8[0m[31m.         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: pharmacokinetics: Gender In a pooled analysis of [0m[1;31m38[0m[31m women and [0m[1;31m298[0m[31m men participating in clinical pharmacology studies, there was no significant difference in the mean [0m[1;31m([0m[31mÂ±SD[0m[1;31m)[0m[31m [0m
[31mtigecycline clearance between women [0m[1;31m([0m[1;31m20.7[0m[31mÂ±[0m[1;31m6.5[0m[31m L/h[0m[1;31m)[0m[31m and men [0m[1;31m([0m[1;31m22.8[0m[31mÂ±[0m[1;31m8.7[0m[31m L/h[0m[1;31m)[0m[31m. Therefore, no dosage adjustment is necessary based on gender. Race In a pooled analysis of [0m[1;31m73[0m[31m Asian subjects, [0m[1;31m53[0m[31m Black [0m
[31msubjects, [0m[1;31m15[0m[31m Hispanic subjects, [0m[1;31m190[0m[31m White subjects, and [0m[1;31m3[0m[31m subjects classified as â€œotherâ€ participating in clinical pharmacology studies, there was no significant difference in the mean [0m[1;31m([0m[31mÂ±SD[0m[1;31m)[0m[31m [0m
[31mtigecycline clearance among the Asian subjects [0m[1;31m([0m[1;31m28.8[0m[31mÂ±[0m[1;31m8.8[0m[31m L/h[0m[1;31m)[0m[31m, Black subjects [0m[1;31m([0m[1;31m23.0[0m[31mÂ±[0m[1;31m7.8[0m[31m L/h[0m[1;31m)[0m[31m, Hispanic subjects [0m[1;31m([0m[1;31m24.3[0m[31mÂ±[0m[1;31m6.5[0m[31m L/h[0m[1;31m)[0m[31m, White subjects [0m[1;31m([0m[1;31m22.1[0m[31mÂ±[0m[1;31m8.9[0m[31m L/h[0m[1;31m)[0m[31m, and â€œotherâ€ subjects [0m[1;31m([0m[1;31m25[0m[31m. TIGECYCLINE: [0m
[31mpharmacokinetics: [0m[1;31m0[0m[31mÂ±[0m[1;31m4.8[0m[31m L/h[0m[1;31m)[0m[31m. Therefore, no dosage adjustment is necessary based on race. Drug Interaction Studies Digoxin Tigecycline for injection [0m[1;31m([0m[1;31m100[0m[31m mg followed by [0m[1;31m50[0m[31m mg every [0m[1;31m12[0m[31m hours[0m[1;31m)[0m[31m and [0m
[31mdigoxin [0m[1;31m([0m[1;31m0.5[0m[31m mg followed by [0m[1;31m0.25[0m[31m mg, orally, every [0m[1;31m24[0m[31m hours[0m[1;31m)[0m[31m were co-administered to healthy subjects in a drug interaction study. Tigecycline slightly decreased the C max of digoxin by [0m[1;31m13[0m[31m%, but did [0m
[31mnot affect the AUC or clearance of digoxin. This small change in C max did not affect the steady-state pharmacodynamic effects of digoxin as measured by changes in ECG intervals. In addition, digoxin [0m
[31mdid not affect the pharmacokinetic profile of tigecycline. Therefore, no dosage adjustment of either drug is necessary when tigecycline for injection is administered with digoxin. TIGECYCLINE: [0m
[31mpharmacokinetics: Warfarin Concomitant administration of tigecycline for injection [0m[1;31m([0m[1;31m100[0m[31m mg followed by [0m[1;31m50[0m[31m mg every [0m[1;31m12[0m[31m hours[0m[1;31m)[0m[31m and warfarin [0m[1;31m([0m[1;31m25[0m[31m mg single-dose[0m[1;31m)[0m[31m to healthy subjects resulted in a decrease[0m
[31min clearance of Râ€‘warfarin and Sâ€‘warfarin by [0m[1;31m40[0m[31m% and [0m[1;31m23[0m[31m%, an increase in C max by [0m[1;31m38[0m[31m% and [0m[1;31m43[0m[31m% and an increase in AUC by [0m[1;31m68[0m[31m% and [0m[1;31m29[0m[31m%, respectively. Tigecycline did not significantly alter the effects [0m
[31mof warfarin on INR. In addition, warfarin did not affect the pharmacokinetic profile of tigecycline. However, prothrombin time or other suitable anticoagulation test should be monitored if tigecycline[0m
[31mis administered with warfarin. TIGECYCLINE: pharmacokinetics: In vitro studies in human liver microsomes indicate that tigecycline does not inhibit metabolism mediated by any of the following [0m[1;31m6[0m[31m [0m
[31mcytochrome P450 [0m[1;31m([0m[31mCYP[0m[1;31m)[0m[31m isoforms: 1A2, 2C8, 2C9, 2C19, 2D6, and 3A4. Therefore, tigecycline for injection is not expected to alter the metabolism of drugs metabolized by these enzymes. In addition, [0m
[31mbecause tigecycline is not extensively metabolized, clearance of tigecycline is not expected to be affected by drugs that inhibit or induce the activity of these CYP450 isoforms. In vitro studies [0m
[31musing Caco-[0m[1;31m2[0m[31m cells indicate that tigecycline does not inhibit digoxin flux, suggesting that tigecycline is not a P-glycoprotein [0m[1;31m([0m[31mP-gp[0m[1;31m)[0m[31m inhibitor. TIGECYCLINE: pharmacokinetics: This in vitro [0m
[31minformation is consistent with the lack of effect of tigecycline on digoxin clearance noted in the in vivo drug interaction study described above. Tigecycline is a substrate of P-gp based on an in [0m
[31mvitro study using a cell line overexpressing P-gp. The potential contribution of P-gp-mediated transport to the in vivo disposition of tigecycline is not known. Coadministration of P-gp inhibitors [0m
[1;31m([0m[31me.g., ketoconazole or cyclosporine[0m[1;31m)[0m[31m or P-gp inducers [0m[1;31m([0m[31me.g., rifampicin[0m[1;31m)[0m[31m could affect the pharmacokinetics of tigecycline.         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: openfda: spl_id         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: openfda: package_ndc         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: openfda: spl_set_id         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: openfda: product_ndc         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: openfda: pharm_class_cs         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: adverse_reactions: [0m[1;31m6[0m[31m ADVERSE REACTIONS The following serious adverse reactions are described elsewhere in the labeling: All-Cause Mortality [0m[31m Mortality Imbalance and Lower Cure [0m
[31mRates in Hospital-Acquired Pneumonia [0m[31m Anaphylaxis [0m[1;31m[[0m[31mWarning and Precautions [0m[1;31m([0m[31m [0m[1;31m5.3[0m[31m [0m[1;31m)[0m[1;31m][0m[31m Hepatic Adverse Effects [0m[1;31m[[0m[31mWarnings and Precautions [0m[1;31m([0m[31m [0m[1;31m5.4[0m[31m [0m[1;31m)[0m[1;31m][0m[31m Pancreatitis [0m[1;31m[[0m[31mWarnings and Precautions [0m[1;31m([0m[31m [0m[1;31m5.5[0m[31m [0m[1;31m)[0m[1;31m][0m[31m The most [0m
[31mcommon adverse reactions [0m[1;31m([0m[31mincidence [0m[1;31m>[0m[1;31m5[0m[31m%[0m[1;31m)[0m[31m are nausea, vomiting, diarrhea, abdominal pain, headache, and increased SGPT. [0m[1;31m([0m[31m [0m[1;31m6.1[0m[31m [0m[1;31m)[0m[31m To report SUSPECTED ADVERSE REACTIONS, contact Apotex at [0m[1;31m1[0m[31m-[0m[1;31m800[0m[31m-[0m[1;31m706[0m[31m-[0m[1;31m5575[0m[31m [0m
[31mor FDA at [0m[1;31m1[0m[31m-[0m[1;31m800[0m[31m-FDA-[0m[1;31m1088[0m[31m or www. TIGECYCLINE: adverse_reactions: da.gov/medwatch [0m[1;31m6.1[0m[31m Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction [0m
[31mrates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In clinical trials, [0m[1;31m2514[0m
[31mpatients were treated with tigecycline for injection. Tigecycline for injection was discontinued due to adverse reactions in [0m[1;31m7[0m[31m% of patients compared to [0m[1;31m6[0m[31m% for all comparators. Table [0m[1;31m1[0m[31m shows the [0m
[31mincidence of adverse reactions through test of cure reported in â‰¥[0m[1;31m2[0m[31m% of patients in these trials. Table [0m[1;31m1[0m[31m. TIGECYCLINE: adverse_reactions: Incidence [0m[1;31m([0m[31m%[0m[1;31m)[0m[31m of Adverse Reactions Through Test of Cure [0m
[31mReported in â‰¥ [0m[1;31m2[0m[31m% of Patients Treated in Clinical Studies Body System Tigecycline for injection Comparators a Adverse Reactions [0m[1;31m([0m[31mN[0m[31m=[0m[1;31m2514[0m[1;31m)[0m[31m [0m[1;31m([0m[31mN[0m[31m=[0m[1;31m2307[0m[1;31m)[0m[31m a Vancomycin/Aztreonam, Imipenem/Cilastatin, [0m
[31mLevofloxacin, Linezolid. b LFT abnormalities in tigecycline for injection-treated patients were reported more frequently in the post therapy period than those in comparator-treated patients, which [0m
[31moccurred more often on therapy.         [0m
[31mSOURCE:TIGECYCLINE label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32m DO-NOT-KNOW[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does TIGECYCLINE increase or decrease the risk of gastrointestinal ulcer hospitalization?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"tigecycline"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mNo relevant extracts found for Does TIGECYCLINE increase or decrease the risk of [0m
[31mgastrointestinal ulcer hospitalization?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-TIGECYCLINE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-TIGECYCLINE[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-TIGECYCLINE[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-TIGECYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-TIGECYCLINE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-TIGECYCLINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does TIGECYCLINE increase or decrease the risk of gastrointestinal ulcer hospitalization?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-TIGECYCLINE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes TIGECYCLINE increase or decrease the risk[0m
[32mof gastrointestinal ulcer hospitalization?[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-TIGECYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-TIGECYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-TIGECYCLINE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes TIGECYCLINE increase or decrease the risk of gastrointestinal ulcer hospitalization?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does TIGECYCLINE increase or decrease the risk of gastrointestinal ulcer hospitalization?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"tigecycline"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31mCONTENT: TIGECYCLINE: clinical_studies_table: [0m[1;31m<[0m[1;31mtable[0m[31m [0m[31mID[0m[31m=[0m[31m"t11"[0m[31m [0m[31mwidth[0m[31m=[0m[31m"100[0m[31m%"[0m[31m><caption [0m[31mID[0m[31m=[0m[31m"G27e24559[0m[31m-6ed6-49f7-a922-9571f94945ca"[0m[31m>Table [0m[1;31m10[0m[31m. Post-hoc Analysis of Clinical Cure Rates in Patients with [0m
[31mCommunity-Acquired Bacterial Pneumonia Based on Risk of Mortality<sup>a<[0m[31m/[0m[31msup[0m[31m><[0m[31m/[0m[31mcaption[0m[31m><colgroup><col [0m[31malign[0m[31m=[0m[31m"left"[0m[31m [0m[31mwidth[0m[31m=[0m[31m"25[0m[31m%"[0m[31m/[0m[31m><col [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mwidth[0m[31m=[0m[31m"25[0m[31m%"[0m[31m/[0m[31m><col [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mwidth[0m[31m=[0m[31m"25[0m[31m%"[0m[31m/[0m[31m><col [0m
[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mwidth[0m[31m=[0m[31m"25[0m[31m%"[0m[31m/[0m[31m><[0m[31m/[0m[31mcolgroup[0m[31m><thead><tr><th/><th>Tigecycline for injection<[0m[31m/[0m[31mth[0m[31m><th>Levofloxacin<[0m[31m/[0m[31mth[0m[31m><th/><[0m[31m/[0m[31mtr[0m[31m><tr><th/><th>n/N [0m[1;31m([0m[31m%[0m[1;31m)[0m[31m <[0m[31m/[0m[31mth[0m[31m><th>n/N [0m[1;31m([0m[31m%[0m[1;31m)[0m[31m <[0m[31m/[0m[31mth[0m[31m><th>[0m[1;31m95[0m[31m% [0m
[31mCI<sup>b<[0m[31m/[0m[31msup[0m[31m><[0m[31m/[0m[31mth[0m[31m><[0m[31m/[0m[31mtr[0m[31m><[0m[31m/[0m[31mthead[0m[31m><tfoot><tr><td [0m[31mcolspan[0m[31m=[0m[31m"4"[0m[31m><sup>a<[0m[31m/[0m[31msup[0m[31m TIGECYCLINE: clinical_studies_table: > Patients at higher risk of death include patients with any one of the following: [0m
[31m&#x2265;[0m[1;31m50[0m[31m year of age; PSI score &#x2265;[0m[1;31m3[0m[31m; or bacteremia due to <content [0m[31mstyleCode[0m[31m=[0m[31m"italics"[0m[31m>Streptococcus pneumoniae<[0m[31m/[0m[31mcontent[0m[31m><paragraph><sup>b<[0m[31m/[0m[31msup[0m[31m> [0m[1;31m95[0m[31m% confidence interval for the treatment [0m
[31mdifference<[0m[31m/[0m[31mparagraph[0m[31m><paragraph><sup>c<[0m[31m/[0m[31msup[0m[31m> After at least [0m[1;31m3[0m[31m days of intravenous therapy, a switch to oral levofloxacin [0m[1;31m([0m[1;31m500[0m[31m mg daily[0m[1;31m)[0m[31m was permitted for both treatment arms in Study [0m[1;31m1[0m[31m. TIGECYCLINE: [0m
[31mclinical_studies_table: paragraph><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><[0m[31m/[0m[31mtfoot[0m[31m><tbody><tr><td>Study [0m[1;31m1[0m[31m<sup>c<[0m[31m/[0m[31msup[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> CE <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Higher risk [0m
[31m<[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Yes <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m93[0m[31m/[0m[1;31m103[0m[31m [0m[1;31m([0m[1;31m90.3[0m[1;31m)[0m[31m [0m
[31m<[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m84[0m[31m/[0m[1;31m102[0m[31m [0m[1;31m([0m[1;31m82[0m[31m. TIGECYCLINE: clinical_studies_table: [0m[1;31m4[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m([0m[1;31m-2.3[0m[31m, [0m[1;31m18.2[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> No <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m32[0m[31m/[0m[1;31m35[0m[31m [0m[1;31m([0m[1;31m91.4[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m52[0m[31m/[0m[1;31m54[0m[31m [0m[1;31m([0m[1;31m96.3[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m([0m[1;31m-20.8[0m[31m, [0m[1;31m7[0m[31m. TIGECYCLINE: clinical_studies_table: [0m[1;31m1[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> c-mITT [0m
[31m<[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Higher risk <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> [0m
[31m<[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Yes <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m111[0m[31m/[0m[1;31m142[0m[31m [0m[1;31m([0m[1;31m78.2[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m100[0m[31m/[0m[1;31m134[0m[31m [0m[1;31m([0m[1;31m74.6[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m([0m[1;31m-6.9[0m[31m, [0m[1;31m14[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> No <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m38[0m[31m/[0m[1;31m49[0m[31m [0m[1;31m([0m[1;31m77[0m[31m. TIGECYCLINE: clinical_studies_table: [0m[1;31m6[0m[1;31m)[0m[31m [0m
[31m<[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m58[0m[31m/[0m[1;31m69[0m[31m [0m[1;31m([0m[1;31m84.1[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m([0m[1;31m-22.8[0m[31m, [0m[1;31m8[0m[31m. TIGECYCLINE: clinical_studies_table: [0m[1;31m7[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td>Study [0m[1;31m2[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> CE <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Higher risk <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Yes <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m95[0m[31m/[0m[1;31m107[0m[31m [0m[1;31m([0m[1;31m88[0m[31m. TIGECYCLINE: clinical_studies_table: [0m[1;31m8[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m68[0m[31m/[0m[1;31m85[0m[31m [0m[1;31m([0m[1;31m80[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m
[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m([0m[1;31m-2.2[0m[31m, [0m[1;31m20.3[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> No <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m33[0m[31m/[0m[1;31m37[0m[31m [0m[1;31m([0m[1;31m89.2[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m48[0m[31m/[0m[1;31m51[0m[31m [0m[1;31m([0m[1;31m94.1[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m([0m[1;31m-21.1[0m[31m, [0m[1;31m8[0m[31m. TIGECYCLINE: clinical_studies_table: [0m[1;31m6[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> c-mITT <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Higher risk <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Yes [0m
[31m<[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m112[0m[31m/[0m[1;31m134[0m[31m [0m[1;31m([0m[1;31m83.6[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m93[0m[31m/[0m[1;31m120[0m[31m [0m[1;31m([0m[1;31m77.5[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m([0m[1;31m-4.2[0m[31m, [0m[1;31m16.4[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> No <[0m[31m/[0m[31mtd[0m[31m><td [0m
[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m58[0m[31m/[0m[1;31m69[0m[31m [0m[1;31m([0m[1;31m84[0m[31m. TIGECYCLINE: clinical_studies_table: [0m[1;31m1[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m70[0m[31m/[0m[1;31m80[0m[31m [0m[1;31m([0m[1;31m87.5[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m([0m[1;31m-16.2[0m[31m, [0m[1;31m8[0m[31m. TIGECYCLINE: [0m
[31mclinical_studies_table: [0m[1;31m8[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><[0m[31m/[0m[31mtbody[0m[31m><[0m[31m/[0m[31mtable[0m[31m>         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: clinical_studies: [0m[1;31m3[0m[1;31m)[0m[31m Legionella pneumophila [0m[1;31m10[0m[31m/[0m[1;31m10[0m[31m [0m[1;31m([0m[1;31m100.0[0m[1;31m)[0m[31m [0m[1;31m6[0m[31m/[0m[1;31m6[0m[31m [0m[1;31m([0m[1;31m100.0[0m[1;31m)[0m[31m Streptococcus pneumoniae [0m[1;31m([0m[31mpenicillin-susceptible only[0m[1;31m)[0m[31m b [0m[1;31m44[0m[31m/[0m[1;31m46[0m[31m [0m[1;31m([0m[1;31m95.7[0m[1;31m)[0m[31m [0m[1;31m39[0m[31m/[0m[1;31m44[0m[31m [0m[1;31m([0m[1;31m88.6[0m[1;31m)[0m[31m To further evaluate the [0m
[31mtreatment effect of tigecycline, a post-hoc analysis was conducted in CABP patients with a higher risk of mortality, for whom the treatment effect of antibacterial drugs is supported by historical [0m
[31mevidence. The higher-risk group included CABP patients from the two studies with any of the following factors: Age â‰¥[0m[1;31m50[0m[31m years PSI score â‰¥[0m[1;31m3[0m[31m Streptococcus pneumoniae bacteremia The results of this [0m
[31manalysis are shown in Table [0m[1;31m10[0m[31m. Age â‰¥[0m[1;31m50[0m[31m was the most common risk factor in the higher-risk group. Table [0m[1;31m10[0m[31m. TIGECYCLINE: clinical_studies: Post-hoc Analysis of Clinical Cure Rates in Patients with [0m
[31mCommunity-Acquired Bacterial Pneumonia Based on Risk of Mortality a Tigecycline for injection Levofloxacin n/N [0m[1;31m([0m[31m%[0m[1;31m)[0m[31m n/N [0m[1;31m([0m[31m%[0m[1;31m)[0m[31m [0m[1;31m95[0m[31m% CI b a Patients at higher risk of death include patients with any one of [0m
[31mthe following: â‰¥[0m[1;31m50[0m[31m year of age; PSI score â‰¥[0m[1;31m3[0m[31m; or bacteremia due to Streptococcus pneumoniae b [0m[1;31m95[0m[31m% confidence interval for the treatment difference c After at least [0m[1;31m3[0m[31m days of intravenous therapy, a [0m
[31mswitch to oral levofloxacin [0m[1;31m([0m[1;31m500[0m[31m mg daily[0m[1;31m)[0m[31m was permitted for both treatment arms in Study [0m[1;31m1[0m[31m. Study [0m[1;31m1[0m[31m c CE Higher risk Yes [0m[1;31m93[0m[31m/[0m[1;31m103[0m[31m [0m[1;31m([0m[1;31m90.3[0m[1;31m)[0m[31m [0m[1;31m84[0m[31m/[0m[1;31m102[0m[31m [0m[1;31m([0m[1;31m82.4[0m[1;31m)[0m[31m [0m[1;31m([0m[1;31m-2.3[0m[31m, [0m[1;31m18.2[0m[1;31m)[0m[31m No [0m[1;31m32[0m[31m/[0m[1;31m35[0m[31m [0m[1;31m([0m[1;31m91.4[0m[1;31m)[0m[31m [0m[1;31m52[0m[31m/[0m[1;31m54[0m[31m [0m[1;31m([0m[1;31m96.3[0m[1;31m)[0m[31m [0m[1;31m([0m[1;31m-20.8[0m[31m, [0m
[1;31m7[0m[31m. TIGECYCLINE: clinical_studies: [0m[1;31m1[0m[1;31m)[0m[31m c-mITT Higher risk Yes [0m[1;31m111[0m[31m/[0m[1;31m142[0m[31m [0m[1;31m([0m[1;31m78.2[0m[1;31m)[0m[31m [0m[1;31m100[0m[31m/[0m[1;31m134[0m[31m [0m[1;31m([0m[1;31m74.6[0m[1;31m)[0m[31m [0m[1;31m([0m[1;31m-6.9[0m[31m, [0m[1;31m14[0m[1;31m)[0m[31m No [0m[1;31m38[0m[31m/[0m[1;31m49[0m[31m [0m[1;31m([0m[1;31m77.6[0m[1;31m)[0m[31m [0m[1;31m58[0m[31m/[0m[1;31m69[0m[31m [0m[1;31m([0m[1;31m84.1[0m[1;31m)[0m[31m [0m[1;31m([0m[1;31m-22.8[0m[31m, [0m[1;31m8.7[0m[1;31m)[0m[31m Study [0m[1;31m2[0m[31m CE Higher risk Yes [0m[1;31m95[0m[31m/[0m[1;31m107[0m[31m [0m[1;31m([0m[1;31m88.8[0m[1;31m)[0m[31m [0m[1;31m68[0m[31m/[0m[1;31m85[0m[31m [0m[1;31m([0m[1;31m80[0m[1;31m)[0m[31m [0m
[1;31m([0m[1;31m-2.2[0m[31m, [0m[1;31m20.3[0m[1;31m)[0m[31m No [0m[1;31m33[0m[31m/[0m[1;31m37[0m[31m [0m[1;31m([0m[1;31m89.2[0m[1;31m)[0m[31m [0m[1;31m48[0m[31m/[0m[1;31m51[0m[31m [0m[1;31m([0m[1;31m94.1[0m[1;31m)[0m[31m [0m[1;31m([0m[1;31m-21.1[0m[31m, [0m[1;31m8.6[0m[1;31m)[0m[31m c-mITT Higher risk Yes [0m[1;31m112[0m[31m/[0m[1;31m134[0m[31m [0m[1;31m([0m[1;31m83.6[0m[1;31m)[0m[31m [0m[1;31m93[0m[31m/[0m[1;31m120[0m[31m [0m[1;31m([0m[1;31m77.5[0m[1;31m)[0m[31m [0m[1;31m([0m[1;31m-4.2[0m[31m, [0m[1;31m16.4[0m[1;31m)[0m[31m No [0m[1;31m58[0m[31m/[0m[1;31m69[0m[31m [0m[1;31m([0m[1;31m84.1[0m[1;31m)[0m[31m [0m[1;31m70[0m[31m/[0m[1;31m80[0m[31m [0m[1;31m([0m[1;31m87.5[0m[1;31m)[0m[31m [0m[1;31m([0m[1;31m-16.2[0m[31m, [0m[1;31m8[0m[31m.         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: pharmacokinetics: Gender In a pooled analysis of [0m[1;31m38[0m[31m women and [0m[1;31m298[0m[31m men participating in clinical pharmacology studies, there was no significant difference in the mean [0m[1;31m([0m[31mÂ±SD[0m[1;31m)[0m[31m [0m
[31mtigecycline clearance between women [0m[1;31m([0m[1;31m20.7[0m[31mÂ±[0m[1;31m6.5[0m[31m L/h[0m[1;31m)[0m[31m and men [0m[1;31m([0m[1;31m22.8[0m[31mÂ±[0m[1;31m8.7[0m[31m L/h[0m[1;31m)[0m[31m. Therefore, no dosage adjustment is necessary based on gender. Race In a pooled analysis of [0m[1;31m73[0m[31m Asian subjects, [0m[1;31m53[0m[31m Black [0m
[31msubjects, [0m[1;31m15[0m[31m Hispanic subjects, [0m[1;31m190[0m[31m White subjects, and [0m[1;31m3[0m[31m subjects classified as â€œotherâ€ participating in clinical pharmacology studies, there was no significant difference in the mean [0m[1;31m([0m[31mÂ±SD[0m[1;31m)[0m[31m [0m
[31mtigecycline clearance among the Asian subjects [0m[1;31m([0m[1;31m28.8[0m[31mÂ±[0m[1;31m8.8[0m[31m L/h[0m[1;31m)[0m[31m, Black subjects [0m[1;31m([0m[1;31m23.0[0m[31mÂ±[0m[1;31m7.8[0m[31m L/h[0m[1;31m)[0m[31m, Hispanic subjects [0m[1;31m([0m[1;31m24.3[0m[31mÂ±[0m[1;31m6.5[0m[31m L/h[0m[1;31m)[0m[31m, White subjects [0m[1;31m([0m[1;31m22.1[0m[31mÂ±[0m[1;31m8.9[0m[31m L/h[0m[1;31m)[0m[31m, and â€œotherâ€ subjects [0m[1;31m([0m[1;31m25[0m[31m. TIGECYCLINE: [0m
[31mpharmacokinetics: [0m[1;31m0[0m[31mÂ±[0m[1;31m4.8[0m[31m L/h[0m[1;31m)[0m[31m. Therefore, no dosage adjustment is necessary based on race. Drug Interaction Studies Digoxin Tigecycline for injection [0m[1;31m([0m[1;31m100[0m[31m mg followed by [0m[1;31m50[0m[31m mg every [0m[1;31m12[0m[31m hours[0m[1;31m)[0m[31m and [0m
[31mdigoxin [0m[1;31m([0m[1;31m0.5[0m[31m mg followed by [0m[1;31m0.25[0m[31m mg, orally, every [0m[1;31m24[0m[31m hours[0m[1;31m)[0m[31m were co-administered to healthy subjects in a drug interaction study. Tigecycline slightly decreased the C max of digoxin by [0m[1;31m13[0m[31m%, but did [0m
[31mnot affect the AUC or clearance of digoxin. This small change in C max did not affect the steady-state pharmacodynamic effects of digoxin as measured by changes in ECG intervals. In addition, digoxin [0m
[31mdid not affect the pharmacokinetic profile of tigecycline. Therefore, no dosage adjustment of either drug is necessary when tigecycline for injection is administered with digoxin. TIGECYCLINE: [0m
[31mpharmacokinetics: Warfarin Concomitant administration of tigecycline for injection [0m[1;31m([0m[1;31m100[0m[31m mg followed by [0m[1;31m50[0m[31m mg every [0m[1;31m12[0m[31m hours[0m[1;31m)[0m[31m and warfarin [0m[1;31m([0m[1;31m25[0m[31m mg single-dose[0m[1;31m)[0m[31m to healthy subjects resulted in a decrease[0m
[31min clearance of Râ€‘warfarin and Sâ€‘warfarin by [0m[1;31m40[0m[31m% and [0m[1;31m23[0m[31m%, an increase in C max by [0m[1;31m38[0m[31m% and [0m[1;31m43[0m[31m% and an increase in AUC by [0m[1;31m68[0m[31m% and [0m[1;31m29[0m[31m%, respectively. Tigecycline did not significantly alter the effects [0m
[31mof warfarin on INR. In addition, warfarin did not affect the pharmacokinetic profile of tigecycline. However, prothrombin time or other suitable anticoagulation test should be monitored if tigecycline[0m
[31mis administered with warfarin. TIGECYCLINE: pharmacokinetics: In vitro studies in human liver microsomes indicate that tigecycline does not inhibit metabolism mediated by any of the following [0m[1;31m6[0m[31m [0m
[31mcytochrome P450 [0m[1;31m([0m[31mCYP[0m[1;31m)[0m[31m isoforms: 1A2, 2C8, 2C9, 2C19, 2D6, and 3A4. Therefore, tigecycline for injection is not expected to alter the metabolism of drugs metabolized by these enzymes. In addition, [0m
[31mbecause tigecycline is not extensively metabolized, clearance of tigecycline is not expected to be affected by drugs that inhibit or induce the activity of these CYP450 isoforms. In vitro studies [0m
[31musing Caco-[0m[1;31m2[0m[31m cells indicate that tigecycline does not inhibit digoxin flux, suggesting that tigecycline is not a P-glycoprotein [0m[1;31m([0m[31mP-gp[0m[1;31m)[0m[31m inhibitor. TIGECYCLINE: pharmacokinetics: This in vitro [0m
[31minformation is consistent with the lack of effect of tigecycline on digoxin clearance noted in the in vivo drug interaction study described above. Tigecycline is a substrate of P-gp based on an in [0m
[31mvitro study using a cell line overexpressing P-gp. The potential contribution of P-gp-mediated transport to the in vivo disposition of tigecycline is not known. Coadministration of P-gp inhibitors [0m
[1;31m([0m[31me.g., ketoconazole or cyclosporine[0m[1;31m)[0m[31m or P-gp inducers [0m[1;31m([0m[31me.g., rifampicin[0m[1;31m)[0m[31m could affect the pharmacokinetics of tigecycline.         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: openfda: spl_id         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: openfda: package_ndc         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: openfda: spl_set_id         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: openfda: product_ndc         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: openfda: pharm_class_cs         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: adverse_reactions: [0m[1;31m6[0m[31m ADVERSE REACTIONS The following serious adverse reactions are described elsewhere in the labeling: All-Cause Mortality [0m[31m Mortality Imbalance and Lower Cure [0m
[31mRates in Hospital-Acquired Pneumonia [0m[31m Anaphylaxis [0m[1;31m[[0m[31mWarning and Precautions [0m[1;31m([0m[31m [0m[1;31m5.3[0m[31m [0m[1;31m)[0m[1;31m][0m[31m Hepatic Adverse Effects [0m[1;31m[[0m[31mWarnings and Precautions [0m[1;31m([0m[31m [0m[1;31m5.4[0m[31m [0m[1;31m)[0m[1;31m][0m[31m Pancreatitis [0m[1;31m[[0m[31mWarnings and Precautions [0m[1;31m([0m[31m [0m[1;31m5.5[0m[31m [0m[1;31m)[0m[1;31m][0m[31m The most [0m
[31mcommon adverse reactions [0m[1;31m([0m[31mincidence [0m[1;31m>[0m[1;31m5[0m[31m%[0m[1;31m)[0m[31m are nausea, vomiting, diarrhea, abdominal pain, headache, and increased SGPT. [0m[1;31m([0m[31m [0m[1;31m6.1[0m[31m [0m[1;31m)[0m[31m To report SUSPECTED ADVERSE REACTIONS, contact Apotex at [0m[1;31m1[0m[31m-[0m[1;31m800[0m[31m-[0m[1;31m706[0m[31m-[0m[1;31m5575[0m[31m [0m
[31mor FDA at [0m[1;31m1[0m[31m-[0m[1;31m800[0m[31m-FDA-[0m[1;31m1088[0m[31m or www. TIGECYCLINE: adverse_reactions: da.gov/medwatch [0m[1;31m6.1[0m[31m Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction [0m
[31mrates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In clinical trials, [0m[1;31m2514[0m
[31mpatients were treated with tigecycline for injection. Tigecycline for injection was discontinued due to adverse reactions in [0m[1;31m7[0m[31m% of patients compared to [0m[1;31m6[0m[31m% for all comparators. Table [0m[1;31m1[0m[31m shows the [0m
[31mincidence of adverse reactions through test of cure reported in â‰¥[0m[1;31m2[0m[31m% of patients in these trials. Table [0m[1;31m1[0m[31m. TIGECYCLINE: adverse_reactions: Incidence [0m[1;31m([0m[31m%[0m[1;31m)[0m[31m of Adverse Reactions Through Test of Cure [0m
[31mReported in â‰¥ [0m[1;31m2[0m[31m% of Patients Treated in Clinical Studies Body System Tigecycline for injection Comparators a Adverse Reactions [0m[1;31m([0m[31mN[0m[31m=[0m[1;31m2514[0m[1;31m)[0m[31m [0m[1;31m([0m[31mN[0m[31m=[0m[1;31m2307[0m[1;31m)[0m[31m a Vancomycin/Aztreonam, Imipenem/Cilastatin, [0m
[31mLevofloxacin, Linezolid. b LFT abnormalities in tigecycline for injection-treated patients were reported more frequently in the post therapy period than those in comparator-treated patients, which [0m
[31moccurred more often on therapy.         [0m
[31mSOURCE:TIGECYCLINE label[0m

 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-TIGECYCLINE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-TIGECYCLINE[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-TIGECYCLINE[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-TIGECYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-TIGECYCLINE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-TIGECYCLINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does TIGECYCLINE increase or decrease the risk of gastrointestinal ulcer hospitalization?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-TIGECYCLINE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes TIGECYCLINE increase or decrease the risk[0m
[32mof gastrointestinal ulcer hospitalization?[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-TIGECYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-TIGECYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-TIGECYCLINE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes TIGECYCLINE increase or decrease the risk of gastrointestinal ulcer hospitalization?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does TIGECYCLINE increase or decrease the risk of gastrointestinal ulcer hospitalization?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"tigecycline"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mNo relevant extracts found for Does TIGECYCLINE increase or decrease the risk of [0m
[31mgastrointestinal ulcer hospitalization?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-TIGECYCLINE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-TIGECYCLINE[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-TIGECYCLINE[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-TIGECYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-TIGECYCLINE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-TIGECYCLINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Tigecycline"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-TIGECYCLINE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mTigecycline[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-TIGECYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-TIGECYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-TIGECYCLINE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mTigecycline[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Tigecycline"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"tigecycline"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31mCONTENT: TIGECYCLINE: microbiology: [0m[1;31m12.4[0m[31m Microbiology Mechanism of Action Tigecycline inhibits protein translation in bacteria by binding to the 30S ribosomal subunit and blocking entry of amino-acyl [0m
[31mtRNA molecules into the A site of the ribosome. This prevents incorporation of amino acid residues into elongating peptide chains. In general, tigecycline is considered bacteriostatic; however, [0m
[31mtigecycline for injection has demonstrated bactericidal activity against isolates of S. pneumoniae and L. pneumophila . Resistance To date there has been no cross-resistance observed between [0m
[31mtigecycline and other antibacterial drugs. Tigecycline is less affected by the two major tetracycline-resistance mechanisms, ribosomal protection and efflux. TIGECYCLINE: microbiology: Additionally, [0m
[31mtigecycline is not affected by resistance mechanisms such as beta-lactamases [0m[1;31m([0m[31mincluding extended spectrum beta-lactamases[0m[1;31m)[0m[31m, target-site modifications, macrolide efflux pumps or enzyme target changes [0m
[1;31m([0m[31me.g. gyrase/topoisomerases[0m[1;31m)[0m[31m. However, some ESBL-producing isolates may confer resistance to tigecycline via other resistance mechanisms. Tigecycline resistance in some bacteria [0m[1;31m([0m[31me.g. Acinetobacter [0m
[31mcalcoaceticus-Acinetobacter baumannii complex[0m[1;31m)[0m[31m is associated with multi-drug resistant [0m[1;31m([0m[31mMDR[0m[1;31m)[0m[31m efflux pumps. Interaction with Other Antimicrobials In vitro studies have not demonstrated antagonism [0m
[31mbetween tigecycline and other commonly used antibacterial drugs. Antimicrobial Activity Tigecycline has been shown to be active against most of the following microorganisms, both in vitro and in [0m
[31mclinical infections [0m[31m . TIGECYCLINE: microbiology: Gram-positive bacteria Enterococcus faecalis [0m[1;31m([0m[31mvancomycin-susceptible isolates[0m[1;31m)[0m[31m Staphylococcus aureus [0m[1;31m([0m[31mmethicillin-susceptible and -resistant isolates[0m[1;31m)[0m
[31mStreptococcus agalactiae Streptococcus anginosus group [0m[1;31m([0m[31mincludes S. anginosus, S. intermedius, and S. TIGECYCLINE: microbiology: constellatus [0m[1;31m)[0m[31m Streptococcus pneumoniae [0m[1;31m([0m[31mpenicillin-susceptible [0m
[31misolates[0m[1;31m)[0m[31m Streptococcus pyogenes Gram-negative bacteria Citrobacter freundii Enterobacter cloacae Escherichia coli Haemophilus influenzae Klebsiella oxytoca Klebsiella pneumoniae Legionella [0m
[31mpneumophila Anaerobic bacteria Bacteroides fragilis Bacteroides thetaiotaomicron Bacteroides uniformis Bacteroides vulgatus Clostridium perfringens Peptostreptococcus micros The following in vitro [0m
[31mdata are available, but their clinical significance is unknown. At least [0m[1;31m90[0m[31m percent of the following bacteria exhibit an in vitro minimum inhibitory concentration [0m[1;31m([0m[31mMIC[0m[1;31m)[0m[31m less than or equal to the [0m
[31msusceptible breakpoint for tigecycline against isolates of similar genus or organism group. TIGECYCLINE: microbiology: However, the efficacy of tigecycline in treating clinical infections caused by [0m
[31mthese bacteria has not been established in adequate and well-controlled clinical trials. TIGECYCLINE: microbiology: Gram-positive bacteria Enterococcus avium Enterococcus casseliflavus Enterococcus [0m
[31mfaecalis [0m[1;31m([0m[31mvancomycin-resistant isolates[0m[1;31m)[0m[31m Enterococcus faecium [0m[1;31m([0m[31mvancomycin-susceptible and -resistant isolates[0m[1;31m)[0m[31m Enterococcus gallinarum Listeria monocytogenes Staphylococcus epidermidis [0m
[1;31m([0m[31mmethicillin-susceptible and -resistant isolates[0m[1;31m)[0m[31m Staphylococcus haemolyticus Gram-negative bacteria Acinetobacter baumannii* Aeromonas hydrophila Citrobacter koseri Enterobacter aerogenes Haemophilus[0m
[31minfluenzae [0m[1;31m([0m[31mampicillin-resistant[0m[1;31m)[0m[31m Haemophilus parainfluenzae Pasteurella multocida Serratia marcescens Stenotrophomonas maltophilia Anaerobic bacteria Bacteroides distasonis Bacteroides ovatus [0m
[31mPeptostreptococcus spp. TIGECYCLINE: microbiology: Porphyromonas spp. Prevotella spp. Other bacteria Mycobacterium abscessus Mycobacterium fortuitum *There have been reports of the development of [0m
[31mtigecycline resistance in Acinetobacter infections seen during the course of standard treatment. Such resistance appears to be attributable to an MDR efflux pump mechanism. While monitoring for [0m
[31mrelapse of infection is important for all infected patients, more frequent monitoring in this case is suggested. If relapse is suspected, blood and other specimens should be obtained and cultured for [0m
[31mthe presence of bacteria. All bacterial isolates should be identified and tested for susceptibility to tigecycline and other appropriate antimicrobials. Susceptibility Testing For specific information[0m
[31mregarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: [0m[4;31mhttps://www.fda.gov/STIC.[0m[31m         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: mechanism_of_action: [0m[1;31m12.1[0m[31m Mechanism of Action Tigecycline is a tetracycline class antibacterial [0m[31m .         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: spl_product_data_elements: Tigecycline TIGECYCLINE TIGECYCLINE TIGECYCLINE HYDROCHLORIC ACID SODIUM HYDROXIDE LACTOSE MONOHYDRATE Tigecycline-for-injection-Vial-Label [0m
[31mTigecycline-for-injection-Carton-label         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: contraindications: [0m[1;31m4[0m[31m CONTRAINDICATIONS Tigecycline for injection is contraindicated for use in patients who have known hypersensitivity to tigecycline. Reactions have included [0m
[31manaphylactic reactions [0m[1;31m[[0m[31m see Warnings and Precautions [0m[1;31m([0m[31m [0m[1;31m5.3[0m[31m [0m[1;31m)[0m[31m and Adverse Reactions [0m[1;31m([0m[31m [0m[1;31m6.2[0m[31m [0m[1;31m)[0m[31m [0m[1;31m][0m[31m . Known hypersensitivity to tigecycline.         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: pharmacokinetics: [0m[1;31m61[0m[31m mcgÂ·h/mL[0m[1;31m)[0m[31m of tigecycline in skin blister fluid was approximately [0m[1;31m26[0m[31m% lower than the AUC [0m[1;31m0[0m[31m-12h in the serum of [0m[1;31m10[0m[31m healthy subjects. In a single-dose study, [0m
[31mtigecycline [0m[1;31m100[0m[31m mg was administered to subjects prior to undergoing elective surgery or medical procedure for tissue extraction. Concentrations at [0m[1;31m4[0m[31m hours after tigecycline administration were higher [0m
[31min gallbladder [0m[1;31m([0m[1;31m38[0m[31m-fold, [0m[31mn[0m[31m=[0m[1;31m6[0m[1;31m)[0m[31m, lung [0m[1;31m([0m[1;31m3.7[0m[31m-fold, [0m[31mn[0m[31m=[0m[1;31m5[0m[1;31m)[0m[31m, and colon [0m[1;31m([0m[1;31m2.3[0m[31m-fold, [0m[31mn[0m[31m=[0m[1;31m6[0m[1;31m)[0m[31m, and lower in synovial fluid [0m[1;31m([0m[1;31m0.58[0m[31m-fold, [0m[31mn[0m[31m=[0m[1;31m5[0m[1;31m)[0m[31m, and bone [0m[1;31m([0m[1;31m0.35[0m[31m-fold, [0m[31mn[0m[31m=[0m[1;31m6[0m[1;31m)[0m[31m relative to serum. The concentration of [0m
[31mtigecycline in these tissues after multiple doses has not been studied. Elimination Metabolism Tigecycline is not extensively metabolized. TIGECYCLINE: pharmacokinetics: In vitro studies with [0m
[31mtigecycline using human liver microsomes, liver slices, and hepatocytes led to the formation of only trace amounts of metabolites. In healthy male volunteers receiving [0m[1;31m14[0m[31m C-tigecycline, tigecycline [0m
[31mwas the primary [0m[1;31m14[0m[31m C-labeled material recovered in urine and feces, but a glucuronide, an N-acetyl metabolite, and a tigecycline epimer [0m[1;31m([0m[31meach at no more than [0m[1;31m10[0m[31m% of the administered dose[0m[1;31m)[0m[31m were also [0m
[31mpresent. Tigecycline is a substrate of P-glycoprotein [0m[1;31m([0m[31mP-gp[0m[1;31m)[0m[31m based on an in vitro study using a cell line overexpressing P-gp. The potential contribution of P-gp-mediated transport to the in vivo [0m
[31mdisposition of tigecycline is not known. TIGECYCLINE: pharmacokinetics: Excretion The recovery of total radioactivity in feces and urine following administration of [0m[1;31m14[0m[31m Câ€‘tigecycline indicates that [0m[1;31m59[0m[31m%[0m
[31mof the dose is eliminated by biliary/fecal excretion, and [0m[1;31m33[0m[31m% is excreted in urine. Approximately [0m[1;31m22[0m[31m% of the total dose is excreted as unchanged tigecycline in urine. Overall, the primary route of [0m
[31melimination for tigecycline is biliary excretion of unchanged tigecycline and its metabolites. Glucuronidation and renal excretion of unchanged tigecycline are secondary routes. TIGECYCLINE: [0m
[31mpharmacokinetics: Specific Populations Hepatic Impairment In a study comparing [0m[1;31m10[0m[31m patients with mild hepatic impairment [0m[1;31m([0m[31mChild Pugh A[0m[1;31m)[0m[31m, [0m[1;31m10[0m[31m patients with moderate hepatic impairment [0m[1;31m([0m[31mChild Pugh B[0m[1;31m)[0m[31m, and[0m
[1;31m5[0m[31m patients with severe hepatic impairment [0m[1;31m([0m[31mChild Pugh C[0m[1;31m)[0m[31m to [0m[1;31m23[0m[31m age and weight matched healthy control subjects, the single-dose pharmacokinetic disposition of tigecycline was not altered in patients [0m
[31mwith mild hepatic impairment. However, systemic clearance of tigecycline was reduced by [0m[1;31m25[0m[31m% and the half-life of tigecycline was prolonged by [0m[1;31m23[0m[31m% in patients with moderate hepatic impairment [0m[1;31m([0m[31mChild [0m
[31mPugh B[0m[1;31m)[0m[31m. Systemic clearance of tigecycline was reduced by [0m[1;31m55[0m[31m%, and the half-life of tigecycline was prolonged by [0m[1;31m43[0m[31m% in patients with severe hepatic impairment [0m[1;31m([0m[31mChild Pugh C[0m[1;31m)[0m[31m. TIGECYCLINE: [0m
[31mpharmacokinetics: Dosage adjustment is necessary in patients with severe hepatic impairment [0m[1;31m([0m[31mChild Pugh C[0m[1;31m)[0m[31m [0m[31m . Renal Impairment A single dose study compared [0m[1;31m6[0m[31m subjects with severe renal impairment [0m
[1;31m([0m[31mcreatinine clearance <[0m[1;31m30[0m[31m mL/min[0m[1;31m)[0m[31m, [0m[1;31m4[0m[31m end stage renal disease [0m[1;31m([0m[31mESRD[0m[1;31m)[0m[31m patients receiving tigecycline [0m[1;31m2[0m[31m hours before hemodialysis, [0m[1;31m4[0m[31m ESRD patients receiving tigecycline [0m[1;31m1[0m[31m hour after hemodialysis, and [0m[1;31m6[0m[31m [0m
[31mhealthy control subjects. The pharmacokinetic profile of tigecycline was not significantly altered in any of the renally impaired patient groups, nor was tigecycline removed by hemodialysis. No dosage[0m
[31madjustment of tigecycline for injection is necessary in patients with renal impairment or in patients undergoing hemodialysis.         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: warnings_and_cautions: [0m[1;31m5[0m[31m WARNINGS AND PRECAUTIONS All-Cause Mortality: A meta-analysis of Phase [0m[1;31m3[0m[31m and [0m[1;31m4[0m[31m clinical trials demonstrated an increase in all-cause mortality in [0m
[31mtigecycline for injection-treated patients compared to controls with a risk difference of [0m[1;31m0.6[0m[31m% [0m[1;31m([0m[1;31m95[0m[31m% CI [0m[1;31m0.1[0m[31m, [0m[1;31m1.2[0m[1;31m)[0m[31m. The cause of this increase has not been established. An increase was also seen in a [0m
[31mmeta-analysis limited to the approved indications [0m[1;31m[[0m[1;31m0.6[0m[31m% [0m[1;31m([0m[1;31m95[0m[31m% CI [0m[1;31m0.0[0m[31m, [0m[1;31m1.2[0m[1;31m)[0m[1;31m][0m[31m. The greatest difference in mortality was seen in tigecycline for injection-treated patients with ventilator-associated [0m
[31mpneumonia. [0m[1;31m([0m[31m [0m[1;31m5.1[0m[31m , [0m[1;31m5.2[0m[31m [0m[1;31m)[0m[31m Anaphylactic Reactions: have been reported with tigecycline for injection and may be life-threatening. Avoid use in patients with known hypersensitivity to tetracyclines. [0m[1;31m([0m[31m [0m[1;31m5[0m[31m.[0m
[31mTIGECYCLINE: warnings_and_cautions: [0m[1;31m3[0m[31m [0m[1;31m)[0m[31m Hepatic Adverse Effects: have been reported with tigecycline for injection. Patients who develop abnormal liver function tests during tigecycline for injection [0m
[31mtherapy should be monitored for evidence of worsening hepatic function and evaluated for risk/benefit of continuing tigecycline therapy. [0m[1;31m([0m[31m [0m[1;31m5.4[0m[31m [0m[1;31m)[0m[31m Pancreatitis: including fatalities, has been reported [0m
[31mwith tigecycline for injection. If pancreatitis is suspected, then consider stopping tigecycline for injection. [0m[1;31m([0m[31m [0m[1;31m5.5[0m[31m [0m[1;31m)[0m[31m Monitoring Blood Coagulation Parameters: Hypofibrinogenemia has been reported [0m
[31mwith tigecycline for injection. Monitor blood coagulation parameters, including fibrinogen, at baseline and regularly during treatment with tigecycline for injection. [0m[1;31m([0m[31m [0m[1;31m5[0m[31m. TIGECYCLINE: [0m
[31mwarnings_and_cautions: [0m[1;31m6[0m[31m [0m[1;31m)[0m[31m Tooth Discoloration and Enamel Hypoplasia: The use of tigecycline for injection during tooth development [0m[1;31m([0m[31mlast half of pregnancy, infancy, and childhood to the age of [0m[1;31m8[0m[31m [0m
[31myears[0m[1;31m)[0m[31m may cause permanent discoloration of the teeth [0m[1;31m([0m[31myellow-gray-brown[0m[1;31m)[0m[31m and enamel hypoplasia. [0m[1;31m([0m[31m [0m[1;31m5.7[0m[31m [0m[1;31m)[0m[31m Inhibition of Bone Growth: The use of tigecycline for injection during the second and third [0m
[31mtrimester of pregnancy, infancy, and childhood up to the age of [0m[1;31m8[0m[31m years may cause reversible inhibition of bone growth. [0m[1;31m([0m[31m [0m[1;31m5.8[0m[31m [0m[1;31m)[0m[31m Clostridium difficile associated Diarrhea [0m[1;31m([0m[31mCDAD[0m[1;31m)[0m[31m: evaluate if diarrhea [0m
[31moccurs. [0m[1;31m([0m[1;31m5.9[0m[31m [0m[1;31m)[0m[31m [0m[1;31m5.1[0m[31m All-Cause Mortality An increase in all-cause mortality has been observed in a meta-analysis of Phase [0m[1;31m3[0m[31m and [0m[1;31m4[0m[31m clinical trials in tigecycline for injection-treated patients versus [0m
[31mcomparator-treated patients. TIGECYCLINE: warnings_and_cautions: In all [0m[1;31m13[0m[31m Phase [0m[1;31m3[0m[31m and [0m[1;31m4[0m[31m trials that included a comparator, death occurred in [0m[1;31m4.0[0m[31m% [0m[1;31m([0m[1;31m150[0m[31m/[0m[1;31m3788[0m[1;31m)[0m[31m of patients receiving tigecycline for [0m
[31minjection and [0m[1;31m3.0[0m[31m% [0m[1;31m([0m[1;31m110[0m[31m/[0m[1;31m3646[0m[1;31m)[0m[31m of patients receiving comparator drugs. In a pooled analysis of these trials, based on a random effects model by trial weight, the adjusted risk difference of all-cause [0m
[31mmortality was [0m[1;31m0.6[0m[31m% [0m[1;31m([0m[1;31m95[0m[31m% CI [0m[1;31m0.1[0m[31m, [0m[1;31m1.2[0m[1;31m)[0m[31m between tigecycline for injection and comparator-treated patients. An analysis of mortality in all trials conducted for approved indications [0m[1;31m([0m[31mcSSSI, cIAI, and [0m
[31mCABP[0m[1;31m)[0m[31m, including post-market trials showed an adjusted mortality rate of [0m[1;31m2.5[0m[31m% [0m[1;31m([0m[1;31m66[0m[31m/[0m[1;31m2640[0m[1;31m)[0m[31m for tigecycline and [0m[1;31m1.8[0m[31m% [0m[1;31m([0m[1;31m48[0m[31m/[0m[1;31m2628[0m[1;31m)[0m[31m for comparator, respectively.         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: warnings_and_cautions: If CDAD is suspected or confirmed, ongoing antibacterial drug use not directed against C. difficile may need to be discontinued. Appropriate fluid and [0m
[31melectrolyte management, protein supplementation, antibacterial drug treatment of C. difficile , and surgical evaluation should be instituted as clinically indicated. [0m[1;31m5.10[0m[31m Sepsis/Septic Shock in [0m
[31mPatients With Intestinal Perforation Monotherapy with tigecycline should be avoided in patients with complicated intra-abdominal infections [0m[1;31m([0m[31mcIAI[0m[1;31m)[0m[31m secondary to clinically apparent intestinal [0m
[31mperforation. In cIAI studies [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m1642[0m[1;31m)[0m[31m, [0m[1;31m6[0m[31m patients treated with tigecycline for injection and [0m[1;31m2[0m[31m patients treated with imipenem/cilastatin presented with intestinal perforations and developed [0m
[31msepsis/septic shock. TIGECYCLINE: warnings_and_cautions: The [0m[1;31m6[0m[31m patients treated with tigecycline for injection had higher APACHE II scores [0m[1;31m([0m[31mmedian = [0m[1;31m13[0m[1;31m)[0m[31m versus the [0m[1;31m2[0m[31m patients treated with [0m
[31mimipenem/cilastatin [0m[1;31m([0m[31mAPACHE II scores = [0m[1;31m4[0m[31m and [0m[1;31m6[0m[1;31m)[0m[31m. Due to differences in baseline APACHE II scores between treatment groups and small overall numbers, the relationship of this outcome to treatment [0m
[31mcannot be established. [0m[1;31m5.11[0m[31m Tetracycline-Class Adverse Effects Tigecycline for injection is structurally similar to tetracycline-class antibacterial drugs and may have similar adverse effects. Such [0m
[31meffects may include: photosensitivity, pseudotumor cerebri, and anti-anabolic action [0m[1;31m([0m[31mwhich has led to increased BUN, azotemia, acidosis, and hyperphosphatemia[0m[1;31m)[0m[31m. [0m[1;31m5[0m[31m. TIGECYCLINE: warnings_and_cautions:[0m
[1;31m12[0m[31m Development of Drug-Resistant Bacteria Prescribing tigecycline for injection in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and [0m
[31mincreases the risk of the development of drug-resistant bacteria.         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: description: [0m[1;31m11[0m[31m DESCRIPTION Tigecycline, USP is a tetracycline class antibacterial for intravenous infusion. The chemical name of tigecycline is [0m[1;31m([0m[31m4S,4aS,5aR,12aS[0m[1;31m)[0m[31m- [0m
[1;31m9[0m[31m-[0m[1;31m[[0m[1;31m2[0m[31m-[0m[1;31m([0m[31mtert-butylamino[0m[1;31m)[0m[31macetamido[0m[1;31m][0m[1;31m-4[0m[31m,[0m[1;31m7[0m[31m-[0m[1;31mbis[0m[1;31m([0m[31mdimethylamino[0m[1;31m)[0m[1;31m-1[0m[31m,[0m[1;31m4[0m[31m,4a,[0m[1;31m5[0m[31m,5a,[0m[1;31m6[0m[31m,[0m[1;31m11[0m[31m,12a-octahydro-[0m[1;31m3[0m[31m,[0m[1;31m10[0m[31m,[0m[1;31m12[0m[31m,12a-tetrahydroxy-[0m[1;31m1[0m[31m,[0m[1;31m11[0m[31m-dioxo-[0m[1;31m2[0m[31m naphthacenecarboxamide. The empirical formula is C [0m[1;31m29[0m[31m H [0m[1;31m39[0m[31m N [0m[1;31m5[0m[31m O [0m[1;31m8[0m[31m and the [0m
[31mmolecular weight is [0m[1;31m585.65[0m[31m. The following represents the chemical structure of tigecycline: Figure [0m[1;31m1[0m[31m: Structure of Tigecycline Tigecycline for injection, USP is an orange lyophilized powder or cake. [0m
[31mTIGECYCLINE: description: Each tigecycline for injection single-dose [0m[1;31m5[0m[31m mL vial contains [0m[1;31m50[0m[31m mg tigecycline, USP lyophilized powder for reconstitution for intravenous infusion and [0m[1;31m100[0m[31m mg of lactose [0m
[31mmonohydrate. The pH is adjusted with hydrochloric acid, and if necessary sodium hydroxide. The product does not contain preservatives. TIGECYCLINE: description: Chemical_Structure         [0m
[31mSOURCE:TIGECYCLINE label[0m

 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: Tigecycline is a tetracycline class antibacterial that inhibits protein translation in bacteria by binding to the 30S ribosomal subunit, preventing the incorporation of amino acid residues [0m
[32minto elongating peptide chains. It is considered bacteriostatic but has shown bactericidal activity against certain bacteria such as S. pneumoniae and L. pneumophila. Tigecycline is active against a [0m
[32mvariety of microorganisms, including both Gram-positive and Gram-negative bacteria, as well as anaerobic bacteria. It is not extensively metabolized and is primarily eliminated by biliary/fecal [0m
[32mexcretion. Tigecycline is contraindicated in patients with known hypersensitivity to the drug, and its use has been associated with an increase in all-cause mortality compared to controls in clinical [0m
[32mtrials. It should be avoided in patients with complicated intra-abdominal infections secondary to clinically apparent intestinal perforation. The drug is structurally similar to other tetracyclines [0m
[32mand may have similar adverse effects, such as photosensitivity, pseudotumor cerebri, and anti-anabolic action.[0m

[32mSOURCE: TIGECYCLINE label[0m
[32mEXTRACT_START_END: Tigecycline inhibits protein [0m[32m...[0m[32m anti-anabolic action.[0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-TIGECYCLINE[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: Tigecycline is a tetracycline class [0m
[34mantibacterial that inhibits protein translation in bacteria by binding to the 30S ribosomal subunit, preventing the incorporation of amino acid residues into elongating peptide chains. It is [0m
[34mconsidered bacteriostatic but has shown bactericidal activity against certain bacteria such as S. pneumoniae and L. pneumophila. Tigecycline is active against a variety of microorganisms, including [0m
[34mboth Gram-positive and Gram-negative bacteria, as well as anaerobic bacteria. It is not extensively metabolized and is primarily eliminated by biliary/fecal excretion. Tigecycline is contraindicated [0m
[34min patients with known hypersensitivity to the drug, and its use has been associated with an increase in all-cause mortality compared to controls in clinical trials. It should be avoided in patients [0m
[34mwith complicated intra-abdominal infections secondary to clinically apparent intestinal perforation. The drug is structurally similar to other tetracyclines and may have similar adverse effects, such [0m
[34mas photosensitivity, pseudotumor cerebri, and anti-anabolic action.[0m

[34mSOURCE: TIGECYCLINE label[0m
[34mEXTRACT_START_END: Tigecycline inhibits protein [0m[34m...[0m[34m anti-anabolic action.[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-TIGECYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-TIGECYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-TIGECYCLINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does TIGECYCLINE increase or decrease the risk of gastrointestinal ulcer hospitalization?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I sent a message to FDAHandler asking whether TIGECYCLINE increases or decreases the risk of gastrointestinal ulcer hospitalization."[0m[32m,[0m
[32m      [0m[32m"FDAHandler provided information about TIGECYCLINE, including its mechanism of action, activity against microorganisms, metabolism, excretion, contraindications, and association with increased [0m
[32mall-cause mortality in clinical trials. However, there was no specific mention of gastrointestinal ulcer hospitalization."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"DO-NOT-KNOW"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-TIGECYCLINE[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-TIGECYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-TIGECYCLINE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-TIGECYCLINE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does TIGECYCLINE increase or decrease the risk of gastrointestinal ulcer hospitalization?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I sent a message to FDAHandler asking whether TIGECYCLINE increases or decreases the risk of gastrointestinal ulcer hospitalization."[0m[34m,[0m
[34m      [0m[34m"FDAHandler provided information about TIGECYCLINE, including its mechanism of action, activity against microorganisms, metabolism, excretion, contraindications, and association with increased [0m
[34mall-cause mortality in clinical trials. However, there was no specific mention of gastrointestinal ulcer hospitalization."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"DO-NOT-KNOW"[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does TIGECYCLINE increase or decrease the risk of gastrointestinal ulcer hospitalization?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I sent a message to FDAHandler asking whether TIGECYCLINE increases or decreases the risk of gastrointestinal ulcer hospitalization.[0m
[1;31m2[0m[31m. FDAHandler provided information about TIGECYCLINE, including its mechanism of action, activity against microorganisms, metabolism, excretion, contraindications, and association with increased [0m
[31mall-cause mortality in clinical trials. However, there was no specific mention of gastrointestinal ulcer hospitalization.[0m
[31m        -----[0m
[31m        Final answer: DO-NOT-KNOW[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-TIGECYCLINE[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-TIGECYCLINE[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was [0m
[31mprovided.[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-TIGECYCLINE[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-TIGECYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-TIGECYCLINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m

[32mThe FDAHandler provided information about TIGECYCLINE, including its mechanism of action, activity against microorganisms, metabolism, excretion, contraindications, and association with increased [0m
[32mall-cause mortality in clinical trials. However, there was no specific mention of gastrointestinal ulcer hospitalization in the information provided. Therefore, I cannot determine whether TIGECYCLINE [0m
[32mincreases or decreases the risk of gastrointestinal ulcer hospitalization based on the FDA label data.[0m
